Pernix therapeutics holdings, inc. (PTX)
CashFlow / Yearly
Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10
Net loss

-77,141

-169,590

-148,315

-35,286

-25,635

-1,410

8,347

9,308

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

370

704

361

331

672

324

97

61

Amortization of intangibles

72,965

85,511

94,334

32,668

8,004

-

-

-

Amortization of intangibles

-

-

-

-

-

2,878

2,205

1,177

Amortization of deferred financing costs

3,296

2,440

2,730

2,333

1,295

0

0

-

Accretion expense

5,279

4,057

2,286

0

0

-

-

-

PIK interest payable

233

0

-

-

-

-

-

-

Interest accretion of notes receivable

-

-

-127

-292

-114

0

0

-

Impairment charge to fair value of land

-

-

-

-

-

-

380

-

Impairment charge to fair value of land

-

-

-

-

-

-

-

0

Deferred income benefit

-238

-200

6,746

-11,753

-22,516

-1,836

-2,273

-3,055

Gain on sale of investment

-

-

-

0

3,605

-

-

-

Loss on disposal of fixed assets

0

-35

-19

-242

-208

-26

0

-

Gain on sale of investment

-

-

-

-

-

0

0

-

Stock compensation expense

2,491

2,718

5,944

4,686

2,049

2,654

1,283

464

Fair market value change in contingent consideration

-1,045

-11,652

-138

0

7,556

-

-

-

Expense for stock options issued in exchange for services

-

-

-

119

548

685

312

-

Cancellation of ParaPRO stock options in connection with termination of contract

-

-

-

-1,294

0

0

-

-

Fair market value change in derivative liability

-47

-8,935

-19,315

0

0

-

-

-

Gain from legal settlement

10,476

0

-

-

-

-

-

-

Gain from exchange of debt

14,650

0

1,112

0

0

-

-

-

Gain from sale of non-core assets

2,000

0

-

-

-

-

-

-

Gain on contingent consideration and put right

-

-

-

0

16,269

-

-

-

Issuance of stock for inducement

-

-

19,500

0

0

-

-

-

Change in fair value of contingent consideration and put right

-

-

-

-

-

0

0

-

Gain on contingent consideration and put right

-

-

-

-

-

0

0

-

Loss on impairment

-

-

24,352

0

19,429

0

0

-

Impairment of fixed assets and intangibles

18,525

56,143

-

-

-

-

-

-

Loss on sale of PML (including impairment)

-

-

-

6,659

0

0

-

-

(Increase) decrease in operating assets, net of effects of acquisitions:
Gain from bargain purchase from Macoven acquisition

-

-

-

-

-

-

-

881

Loss from the operations of the joint venture

-

-

-

-

-

240

814

0

Accounts receivable

-5,412

-11,009

17,082

18,480

-12,163

3,886

5,843

8,361

Income tax receivable

-1,291

-5,321

4,145

6,592

-642

-

-

-2,049

Income taxes

-

-

-

-

-

-1,335

-2,237

-

Inventory

-2,379

-2,260

-444

-1,880

-7,406

650

2,115

1,265

Prepaid expenses and other assets

-3,830

533

-2,471

2,144

2,180

180

274

-170

Increase (decrease) in operating liabilities, net of effects of acquisitions:
Other assets - long term

-

-

-

-

-

-

-

-118

Accounts payable and accrued expenses

-2,115

-7,960

6,682

12,161

-3,398

-1,843

739

1,575

Accrued allowances

-4,652

-1,717

10,074

18,318

-3,075

-

-

-

Arbitration award

-6,900

17,522

0

-

-

-

-

-

Accrued allowances

-

-

-

-

-

1,544

7,960

3,304

Accrued expenses and personnel expenses

-

-

-

-

-

863

-

-

Interest payable

-518

-1,006

2,291

10,012

100

0

-

-

Other liabilities

-2,228

-2,628

-4,973

-4,672

10,189

-

-

-

Other liabilities

-

-

-

-

-

0

-

-

Net cash used in operating activities

-5,939

-16,501

-14,749

8,896

-6,531

-1,926

9,397

4,666

Cash flows from investing activities:
Acquisition of Macoven, net of cash acquired of $189,274

-

-

-

-

-

-

-

1,996

Acquisition of Orexigen, net of cash acquired

0

583

87,986

254,950

310

63,729

-

1,500

Acquisition of non-controlling interest in Gaine - initial payment

-

-

-

-

-

-

-

326

Acquisitions

-

-

-

-

-

850

0

250

Proceeds from sale of investment

-

-

-

0

4,605

0

0

-

Payments received on notes receivable

-

-

4,850

4,850

0

0

-

-

Proceeds from sale of PML

-

-

-

1,137

0

0

-

-

Acquisition of Great Southern Laboratories ("GSL")

-

-

-

-

-

-

0

-

Investment in TherapeuticsMD

-

-

-

-

-

-

-1,000

-

Investment in TherapeuticsMD

-

-

-

-

-

-

-

0

Investment in joint venture with SEEK

-

-

-

-

-

-

1,000

1,502

Proceeds from sale of certain Cypress assets

-

-

-

175

19,588

0

0

-

Proceeds from sale of non-core assets

2,000

0

-

43

31

8

0

-

Acquisitions of licenses

-

-

-

-

-

-

0

-

Acquisition of Cypress

-

-

-

-

-

-

0

-

Purchase of software and equipment

18

984

1,212

1,177

528

326

175

119

Net cash used in investing activities

1,982

-1,567

-84,348

-249,922

23,386

-64,897

-2,175

-5,695

Cash flows from financing activities:
Proceeds from issuance of the Treximet Notes

-

-

-

-

-

0

-

-

Cash acquired in connection with the reverse merger, net of costs paid

-

-

-

-

-

-

-

5,965

Net proceeds from revolving credit facility

-

-

-

-

-

-

1,000

5,000

Proceeds from issuance of Convertible Notes

-

-

130,000

65,000

0

0

-

-

Cash acquired in connection with acquisition of Somaxon

-

-

-

0

2,881

0

0

-

Payments on line of credit

-

-

-

-

-

-

0

-

Proceeds from credit facility, net of capitalized loan costs

-

-

-

-

-

40,054

0

-

Payments on contracts payable

-

-

-

2,500

1,700

3,540

1,230

0

Net proceeds from Delayed Draw Term Loan

30,000

0

-10,013

220,000

0

-

-

-

Payments on Treximet Secured Notes

17,511

20,406

-

-

-

-

-

-

Net payments on revolving credit facility

-

-

-

-

-

6,000

0

-

Payment on financing costs

13,587

0

5,349

14,149

0

0

-

-

Payments on Exchangeable Notes

500

0

-

-

-

-

-

-

Net payments on credit facilities

185

-1,000

7,655

-9,515

-25,153

-

-

-

Payment of consent fee

-

-

2,150

0

0

-

-

-

Payments on mortgages and capital leases

52

77

44

46

144

-

-

-

Tax benefit on stock-based awards

-

-

-

-404

147

-

-

-

Distributions to stockholders

-

-

-

-

-

-

-

121

Tax benefit on stock-based awards

-

-

-

-

-

315

137

0

Shares withheld for the payment of taxes

-

-

-117

-1,109

-230

0

0

-

Repurchase of stock

-

-

-

-

-

-

-

849

Proceeds from issuance of stock in additional offering, net of issuance costs of $846 for the year ended December 31, 2012

-

-

-

-

-

23,751

19,259

-

Transfer to/from restricted cash

-

-

-

-

-

-

-500

501

Payments on mortgages and capital leases

-

-

-

-

-

-121

0

-

Principal payments received on notes receivable

-

-

-

-

-

-

113

86

Payment on acquisition obligation - CEDAX

-

-

-

-

-

-

-

4,600

Payment on acquisition obligation - Gaine

-

-

-

-

-

-

-1,000

345

Proceeds from issuance of common stock, net of tax and costs

-

-

-

-

-

836

289

77

Shares withheld for the payment of taxes

112

23

-

-

-

-

-

-

Proceeds from issuance of common stock, net of tax and costs

1,979

19,814

395

2,149

262

-

-

-

Payments on original Midcap Loan

-

-

-

-

-

0

0

-

Payments on term loan

-

-

-

-

-

0

0

-

Stock issuance costs

-

-

-

-

-

0

-

-

Net cash provided by financing activities

402

-1,692

120,377

260,234

-24,231

55,295

19,069

4,710

Net decrease in cash and cash equivalents

-3,555

-19,760

21,280

19,208

-7,376

-11,528

26,291

3,681

Cash paid for income taxes

-

-

-

-

-

2,482

8,911

2,653

Acquisition of product licenses - contract payable balance

-

-

-

-

-

-

-

0

Interest paid during the period

-

-

-

-

-

200

177

19

Acquisition of license - contract payable

-

-

-

-

-

630

90

-

Accrued bonus paid in unrestricted stock

-

-

-

-

-

200

0

-

Accrued severance paid in restricted common stock

-

-

-

-

-

0

0

-

Acquisition of Cypress and Somaxon - Purchase price adjustment (see Note 4)

-

-

-

-

-

0

0

-

Acquisition of Somaxon - Fair value of common stock

-

-

-

-

-

0

0

-

Acquisition of Treximet - warrants issued to Pozen

-

-

-

-

-

0

-

-

Warrants issued to Frontline in connection with the issuance of the February 2014 Convertible Notes

-

-

-

-

-

0

-

-

Acquisition of Cypress - fair value of common stock

-

-

-

-

-

34,300

-

-

Acquisition of GSL - liabilities assumed

-

-

-

-

-

1,700

-

-

Write off/donation of inventory

-

-

-

-

-

-

-

46

Negotiated repurchases of Pernix common stock from insider

-

-

-

-

-

-

-

3,600

Contribution of capital in acquisition of Macoven

-

-

-

-

-

-

-

2,211